Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients

International Journal of Clinical Oncology

Volumn 13, Issue 3, 2008, Pages 206-211

  Ichikawa, Wataru ^a   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

CYP2A6; Dihydropyrimidine dehydrogenase; Orotate phosphoribosyltransferase; Pharmacogenetics; Thymidine phosphorylase; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CISPLATIN; CYTOCHROME P450 2A6; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OROTATE PHOSPHORIBOSYLTRANSFERASE; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; UFT;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA MICROARRAY; DRUG EFFICACY; DRUG METABOLISM; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ARYL HYDROCARBON HYDROXYLASES; DRUG COMBINATIONS; HUMANS; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; PHARMACOGENETICS; STOMACH NEOPLASMS; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 45749123136     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0786-y     Document Type: Review

References (31)

1. Ichikawa W (2006) Prediction of clinical outcome of fluoropyrimidine- based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 9:145-155
2. Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3:912-920
3. Shirasaka T, Shimamato Y, Ohshimo H, et al. (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
4. Boku N, Yamamoto S, Shirao K, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 25:LBA4513
5. Narahara H, Koizumi W, Hara T, et al. (2007) Randomized phase III study of S-1 alone versus S-1+ cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol 25:4514
6. Maring JG, Groen HJ, Wachters FM, et al. (2005) Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5:226-243
7. Heggie GD, Sommadossi JP, Cross DS, et al. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
8. van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939-950
9. Danenberg PV (1977) Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73-92
10. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338
11. Ichikawa W, Uetake H, Shirota Y, et al. (2003) Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89:1486-1492
12. Ichikawa W, Uetake H, Shirota Y, et al. (2003) Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9:786-791
13. Nakajima M, Fukami T, Yamanaka H, et al. (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80:282-297
14. Fujita K, Yamamoto W, Endo H, et al. (2007) Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1. ASCO Meeting Abstracts 25:2504
15. Hirata K, Horikoshi N, Aiba K, et al. (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000-2005
16. Ichikawa W, Takahashi T, Suto K, et al. (2004) Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91:1245-1250
17. Ichikawa W, Takahashi T, Suto K, et al. (2006) Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119:1927-1933
18. Miyamoto S, Boku N, Ohtsu A, et al. (2000) Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 17:653-658
19. Takechi T, Fujioka A, Matsushima E, et al. (2002) Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38:1271-1277
20. Ichikawa W, Takahashi T, Suto K, et al. (2004) Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 112:967-973
21. Takiuchi H, Kawabe S, Gotoh M, et al. (2007) Thymidylate synthase gene expression in primary tumor predicts activity of S-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res 1:171-176
22. Shimizu T, Yamada Y, Yasui H, et al. (2005) Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Res 25:2997-3001
23. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009
24. Peters GJ, Noordhuis P, Van Kuilenburg AB, et al. (2003) Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4- dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 52:1-12
25. Salonga D, Danenberg KD, Johnson M, et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327
26. Wada Y, Yoshida K, Suzuki T, et al. (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119:783-791
27. Kidd EA, Yu J, Li X, et al. (2005) Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 11:2612-2619
28. Lee S, Baek M, Yang H, et al. (2002) Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett 184:197-206
29. Kang HC, Kim IJ, Park JH, et al. (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10:272-284
30. Kim HK, Choi IJ, Kim HS, et al. (2004) DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 316:781-789
31. Ichikawa W, Takahashi T, Sasaki Y (2007) Pharmacogenetic profiling and clinical outcome of patients (pts) with advanced gastric cancer (AGC) treated with S-1 monotherapy. ASCO Meeting Abstracts 25:4600